Ardent Health, Inc. (NYSE:ARDT – Get Free Report) CFO Alfred Lumsdaine acquired 10,000 shares of Ardent Health stock in a transaction dated Friday, June 5th. The stock was purchased at an average price of $8.81 per share, with a total value of $88,100.00. Following the completion of the purchase, the chief financial officer owned 329,183 shares of the company’s stock, valued at approximately $2,900,102.23. The trade was a 3.13% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Ardent Health Price Performance
Shares of NYSE ARDT opened at $8.81 on Tuesday. Ardent Health, Inc. has a 52 week low of $7.71 and a 52 week high of $15.48. The business’s 50 day moving average price is $9.40 and its 200 day moving average price is $9.11. The company has a quick ratio of 2.00, a current ratio of 2.12 and a debt-to-equity ratio of 0.62. The firm has a market cap of $1.26 billion, a P/E ratio of 9.28, a P/E/G ratio of 1.94 and a beta of 0.85.
Ardent Health (NYSE:ARDT – Get Free Report) last posted its quarterly earnings results on Tuesday, May 5th. The company reported $0.28 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.18 by $0.10. The company had revenue of $1.60 billion during the quarter, compared to analyst estimates of $1.58 billion. Ardent Health had a net margin of 2.09% and a return on equity of 13.85%. Ardent Health has set its FY 2026 guidance at 0.900-1.270 EPS. On average, sell-side analysts expect that Ardent Health, Inc. will post 1.12 earnings per share for the current year.
Hedge Funds Weigh In On Ardent Health
Analyst Upgrades and Downgrades
Several equities research analysts have commented on ARDT shares. Royal Bank Of Canada lowered their price target on shares of Ardent Health from $14.00 to $13.00 and set an “outperform” rating on the stock in a report on Monday, March 9th. Leerink Partners decreased their price objective on Ardent Health from $16.00 to $15.00 and set an “outperform” rating for the company in a report on Friday, March 6th. Wall Street Zen upgraded Ardent Health from a “hold” rating to a “buy” rating in a research note on Saturday, May 16th. UBS Group raised their target price on Ardent Health from $13.00 to $13.50 and gave the stock a “buy” rating in a report on Thursday, May 7th. Finally, Zacks Research upgraded Ardent Health from a “strong sell” rating to a “hold” rating in a research report on Wednesday, March 25th. Seven analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, Ardent Health presently has a consensus rating of “Hold” and an average target price of $14.21.
Check Out Our Latest Analysis on Ardent Health
Ardent Health Company Profile
Ardent Health, listed on the New York Stock Exchange under the ticker ARDT, is a healthcare delivery company focused on acquiring, developing and managing acute care hospitals and complementary outpatient facilities across the United States. The company’s integrated platform encompasses both inpatient and outpatient services, designed to provide end-to-end care solutions and address the full continuum of patient needs.
Through its network, Ardent Health operates general hospitals, emergency departments, ambulatory surgery centers, urgent care clinics, rehabilitation and post-acute care facilities.
Further Reading
- Five stocks we like better than Ardent Health
- 3 Stocks With Fresh Catalysts to Watch Before the July 4
- Amprius Insiders Are Selling: Should Investors Be Worried?
- A Weaker Dollar Could Put These 3 Industrial Stocks Back in Focus
- A Market Rotation Toward Quality Will Benefit These 3 ETFs
Receive News & Ratings for Ardent Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ardent Health and related companies with MarketBeat.com's FREE daily email newsletter.
